Vanstar Provides Nelligan Exploration Update globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Vanstar Mining.
GameSquare Esports Inc (CSE:GSQ) (FRA:29Q1), through its Gaming Community Network (GCN) division, has signed a sales partnership with Even Matchup Gaming (EMG). The company said EMG owns and operates major esports events, including Get On My Level, the largest fighting game tournament in Canada, and Let s Make Moves, the largest Super Smash Bros event in the New York area. “We see a lot of potential in helping EMG’s team maximize their sales pipeline,” said Justin Kenna, CEO of GameSquare, in a statement.
Mydecine Innovations Group Inc (NEO:MYCO) (OTCMKTS:MYCOF) (FRA:0NFA) has announced a partnership with LeadGen Labs, a custom synthesis and contract research organization, to support Mydecine’s novel psychedelic drug development efforts and increase the number of novel molecules the company can synthesize concurrently. Following the announcement of the company’s four initial drug candidates, the Denver-based company said it and LeadGen Labs will work to synthesize no
GameSquare Esports Inc (CSE:GSQ) (FRA:29Q1), through its Gaming Community Network (GCN) division, has signed a sales partnership with Even Matchup Gaming (EMG). The company said EMG owns and operates major esports events, including Get On My Level, the largest fighting game tournament in Canada, and Let s Make Moves, the largest Super Smash Bros event in the New York area. “We see a lot of potential in helping EMG’s team maximize their sales pipeline,” said Justin Kenna, CEO of GameSquare, in a statement.
Mydecine Innovations Group Inc (NEO:MYCO) (OTCMKTS:MYCOF) (FRA:0NFA) has announced a partnership with LeadGen Labs, a custom synthesis and contract research organization, to support Mydecine’s novel psychedelic drug development efforts and increase the number of novel molecules the company can synthesize concurrently. Following the announcement of the company’s four initial drug candidates, the Denver-based company said it and LeadGen Labs will work to synthesize no